PG
Therapeutic Areas
Ipsen Pipeline
| Drug | Indication | Phase |
|---|---|---|
| IQIRVO® (elafibranor) | Primary Biliary Cholangitis | Approved |
| Bylvay | Rare liver disease | Approved |
| Ojemda® | Pediatric oncology monotherapy | Regulatory |
| IPN60340 (ICT01) | First-line unfit Acute Myeloid Leukemia | Phase 1/2 |
| Tovorafenib | Pediatric low-grade glioma | Regulatory |
| Somatuline® | Neuroendocrine tumors | Approved |
| Cabometyx® | Renal cell carcinoma, hepatocellular carcinoma | Approved |
| Dysport® | Spasticity, aesthetic applications | Approved |
Leadership Team at Ipsen
DL
David Loew
Chief Executive Officer
AL
Aymeric Le Chatelier
Executive Vice President, Chief Financial Officer
MC
Michelle C. Werner
Executive Vice President, President of North America
PL
Pierrick Lefranc
Executive Vice President Technical Operations
HW
Henry Wheeler
Vice President, Investor Relations
KD
Khalid Deojee
Senior Manager, Investor Relations
AC
Audrey Clapéron
Translational Biology Director
AM
Alison Mason
Cell culture and fermentation specialist
EM
Emilie Manier
Senior Executive Assistant